Turnstone Biologics Corp. (TSBX) Stock Statistics & Valuation Metrics

Turnstone Biologics Corp. has a market cap or net worth of $8.16M. The enterprise value is $214.51M.

Turnstone Biologics Corp. has 23,140,348 shares outstanding. The number of shares has decreased by -2.65% in one year.

Turnstone Biologics Corp.’s return on equity (ROE) is -2.25 and return on invested capital (ROIC) is -219.63%.

The current PE Ratio of Turnstone Biologics Corp. is -0.16. Turnstone Biologics Corp.’s PEG ratio is 0.04.

In the last 12 months, Turnstone Biologics Corp. had revenue of 0.00 and earned -70.84M in profits. Earnings per share was -3.07.

In the last 12 months, operating cash flow was -57.07M and capital expenditures -85.00K, giving a free cash flow of -57.15M billion.

Turnstone Biologics Corp. pays an annual dividend of ―, resulting in a dividend yield of ―

Turnstone Biologics Corp. upcoming earnings date is Aug 13, 2025, Before Open (Confirmed).

Turnstone Biologics Corp. as a current ratio of 4.17, with Debt / Equity ratio of -5.09%

In the past 12 months, Turnstone Biologics Corp. has paid 37.00K in taxes.

Turnstone Biologics Corp. EV to EBITDA ratio is 0.24, with an EV/FCF ratio of 0.24.

Turnstone Biologics Corp. has $21.85M in cash and marketable securities with $690.00K in debt, giving a net cash position of -$21.16M billion.

Gross margin is 97.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Turnstone Biologics Corp. is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold